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Abstract 
Purpose: To examine the protective effects of resveratrol (RESV) against spinal cord ischemic 
reperfusion (SCIR) injury. 
Methods: Forty-eight male rats were divided into six groups: sham-operated (control-I), SCIR-treated 
(SCIR-II), rats receiving 20 mg/kg of RESV with SCIR (RESV 20+SCIR-III), rats receiving 40 mg/kg of 
RESV with SCIR (RESV 40+SCIR-IV), rats receiving 60 mg/kg of RESV with SCIR (RESV 60+SCIR-V), 
and rats receiving 50 mg/kg of methylprednisolone (MP) with SCIR (MP + SCIR-VI), for 7 days prior to 
IR (pre-treatment) and 7 days after IR (post-treatment). 
Results: The levels of oxidative markers (TBARS, MPO) and inflammatory markers (IL-1β, IL-6, TNF-α, 
and NF-p65) were concomitantly suppressed in RESV-treated rats, which showed improved locomotor 
function. A pronounced increase in the activities of antioxidant enzymes (SOD, CAT and GSH) was 
noted in the RESV group compared with the MP and SCIR groups. RESV and MP supplementation 
increased neuronal count with decreased nuclear degeneration. RESV (40 mg) exhibited greater 
protective effect than 20 mg and 60 mg of RESV and 50 mg of MP. 
Conclusion: The results show the neurotherapeutic potential of RESV (40 mg) to attenuate oxidative 
stress and the inflammatory response to SCIR injury. 
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Spinal cord ischemic reperfusion (SCIR) injury is 
a fatal postoperative complication of thoracic-
abdominal aortic aneurysm surgery that 
contributes to paraplegia in about 10 % to 40 % 
of cases [1]. Paraplegia is a medical condition in 
which the sensory or motor part of the lower 
extremities is impaired due to spinal injury, 
resulting in long-term disability [2]. Numerous 
methods or techniques are recommended to 
treat paraplegic conditions, such as draining the 
cerebrospinal fluid, placement of shunts or 
performing a partial cardiopulmonary bypass, 
hypothermia, and administration of 
pharmacological products such as steroids and 
vasodilators [3]. However, these protective 
effects do not completely revert the paraplegic 
condition. Instead, these treatment regimens 
lead to various adverse events that may worsen 
the paraplegic condition.  
 
Many researchers have focused on various 
natural products that may suppress spinal cord 
ischemic injury (SCII) and subsequently prevent 
the paraplegic condition. Several 
pathophysiological events, including excite-
toxicity (glutamate-mediated), energy failure, 
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inflammation, apoptosis, and oxidative stress, 
have been implicated in SCIR injury. Among 
these events, oxidative stress and inflammation 
are the major contributors and initiators of SCIR 
injury [4]. Therefore, choosing an antioxidant and 
an anti-inflammatory agent that alleviate SCIR 
injury would be a promising strategy. Recent 
studies have shown the protective effects of 
various natural antioxidant products against 
SCIR injury [5]. Methylprednisolone (MP) is a 
neuroprotective agent that possesses antioxidant 
and anti-inflammatory properties, and is 
recommended for treating spinal cord injuries [6]; 
thus, MP was used as a standard in the present 
study. 
 
Resveratrol (RESV; 3,4',5-tri-hydroxy stilbene) is 
a phenolic compound commonly found in red 
wine/red grapes, soybeans and pomegranates 
[7]. RESV has two aromatic rings, with the free 
hydroxyl group contributing to its antioxidant and 
free radical scavenging activities [8]. RESV has 
been used as a potential drug for treating 
cardiovascular disease, diabetes, cancer, and 
various neurological disorders [9]. RESV exhibits 
neuroprotective activities due to its antioxidant, 
anti-inflammatory and anti-apoptotic properties 
[10].  
 
RESV induces nitric oxide (NO) production, 
thereby acting as a vasodilatory agent [11]. 
Additionally, RESV readily crosses the blood-
brain barrier, which favors its neuroprotective 
effects in various ischemic models. Several 
studies have shown the neuroprotective effects 
of RESV against SCII in various animal models 
using different treatment regimens [12]. 
However, to date, no studies have explored the 
long-term, dose-dependent protective effects of 
RESV against SCIR injury. Moreover, a 
treatment regimen using RESV (combination of 
both pre- and post-treatment) remains to be 
established. Therefore, in this study, we explored 
the effective dose of RESV against SCIR injury 
based on a combination of both pre- and post-
treatment patterns (pre- and post-ischemic 
conditions) by assessing locomotor capacity, 
neuronal viability, and oxidative and inflammatory 




Drugs and reagents 
 
Resveratrol (RESV), Hematoxylin and eosin (H & 
E) and Methylprednisolone (MP) were procured 
from Sigma Aldrich (St. Louis, MO, USA). 
Paraformaldehyde, physiological saline (0.89 %), 
glycerol, sodium hydroxide, hydrogen peroxide 
were supplied by Lingjin Co. Ltd, Shanghai, 
China. Phosphate buffered saline (PBS) 
readymade buffer Xylene was bought from 
Beijing Zhongshan Golden Bridge Biotechnology 




Healthy, adult male Sprague-Dawley (SD) rats 
weighing 300–320 g were used for the 
experiment. Rats were housed in a steel cage 
under a 12/12-h light/dark cycle. Food and water 
were given ad libitum. The Ethics Committee of 
China approved the animal experiments for the 
present study (protocol ref no. 02315), which 
were conducted according to the guidelines from 
the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. 
 
SCIR injury was performed based on the method 
previously reported by Hwang [13] with slight 
modifications. Briefly, all rats were fasted 
overnight (12 h) and anesthetized with ketamine 
(50 mg/kg) injected intramuscularly. Body 
temperature was maintained at 37 °C using 
warming or heating pads and heating lamps. The 
hair around the neck region (carotid-inguinal) 
was shaved by placing the rats in the supine 
position. A polyethylene catheter (PE-50) was 
inserted into the tail artery to inject heparin and 
monitor the mean distal arterial pressure 
(MDAP). Thereafter, a Fogarty balloon catheter 
(Edwards Life Science, Shanghai, China) was 
inserted via the left femoral artery into the 
proximal descending thoracic aorta 
(approximately 11 cm from the insertion site), 
and the balloon was inflated with saline to induce 
spinal cord ischemia. 
 
Proximal artery pressure was maintained at 80 
mm Hg during aortic occlusion by draining the 
blood from the carotid artery into the external 
blood reservoir filled with heparinized saline. 
Immediate loss of pulse with decreased MDAP 
confirmed aortic occlusion. The balloon was 
deflated after 25 min of ischemia to initiate 
reperfusion by restoring blood flow. Then, the 
catheters were withdrawn and the rats were 
allowed to recover from anesthesia. All 
procedures were performed in sham-operated 
control rats, which served as negative controls, 
except for aortic occlusion. Mean arterial 
pressure, body temperature and heart beat 





Forty-eight male SD rats were divided into six 
treatment groups with eight rats per group. Rats 
received saline (sham-operated control-I), rats 
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subjected to SCIR insult (SCIR-II), rats receiving 
20 mg/kg b.wt of RESV dissolved in 2 % DMSO 
saline via i.p. (RESV 20+SCIR-III), rats receiving 
40 mg/kg b. wt of RESV dissolved in 2 % DMSO 
saline via  i.p. (RESV 40+SCIR-IV), rats 
receiving 60 mg/kg b. wt of RESV dissolved in 2 
% DMSO saline via  i.p. (RESV 60+SCIR-V) and 
rats receiving 50 mg/kg b. wt MP dissolved in 
saline via  i.p. (MP + SCIR-VI) for 7 days prior IR 





Locomotor function (hind limb movement) was 
tested by an independent observer blinded to the 
grouping and experimental design on days 1, 3, 
5 and 7 after SCIR injury using the Basso Beattie 
Bresnahan (BBB) motor rating scale. The rating 
scale has 0 - 21 levels, where the value 0 (no 
detectable hind limb movement), 1 - 8 (rated for 
slight or higher movements of hindlimb joints), 9 
(rated for dorsal stepping), 10 - 20 (rated for 
progressive improved walking ability) and 21 
(normal movement). 
 
After the last neurological assessment (on day 
7), the rats in each group were subdivided into 
two subgroups for histological (n = 4) and 
biochemical analysis (n = 4). On the day 7, all 
rats were euthanized by i.p. pentobarbital sodium 
injection and spinal tissue were removed 
immediately and fixed in 4 % paraformaldehyde 
for morphological studies. Spinal tissue 
homogenate (10 %) was prepared in Tris-HCl 
buffer, centrifuged at 2500 g for 20 min and used 
for biochemical analysis. 
 
Evaluation of edema (water content) 
 
Edema (E) was detected using procedures 
previously published by Mdzinarishvili with a few 
modifications [14]. The wet and dry weights of 
spinal samples were measured to calculate the E 
(water content). E was calculated as the % 
difference between the two weights. 
 
Lipid peroxidation and antioxidant enzyme 
assays 
 
The levels of superoxide dismutase (SOD), 
catalase (CAT) and reduced glutathione (GSH), 
as well as the lipid peroxidation product 
(malondialdehyde, MDA), were measured in 
spinal tissue using commercial kits based on the 
manufacturer's protocols (Nanjing Jiancheng 
Bioengineering Institute, Nanjing, China). 
Bradford method was used to assess protein 
concentration. 
 
Assay of myeloperoxidase activity 
 
Myeloperoxidase (MPO) levels in spinal tissue 
were quantified by using MPO assay kit (Nanjing 
Jiancheng Bioengineering Institute, Nanjing, 
China). One unit of MPO activity was defined as 
the amount of enzyme degrading 1 mmol of 
peroxidase/min at 25 °C and expressed as Unit 
per gram (U/g) weight of wet tissue. 
 
Assay of TNF-α, IL-1β, IL-6 and NF-κB p65 
subunit 
 
The concentration of various proinflammatory 
cytokines such as TNF-α, IL-1β, and IL-6 in 
spinal homogenate were assessed by 
commercially available ELISA kits (sandwich 
enzyme immunoassay) based on the 
manufacturer’s protocol (Thermo Fisher Scientific 
Inc, MA, USA). Similarly, the levels of the NF-κB 
free p65 subunit in the nuclear fraction 
(CellBiolabs Nuclear/Cytosolic Fractionation Kit) 
of the spinal tissue was determined by 
ActivELISA (Imgenex, San Diego, USA) kit. 
 
Histopathological examination 
Four rats in each group were euthanized and the 
spinal cord (tissue) were removed, fixed in 10 % 
buffered formalin for 24 h and embedded in 
paraffin. Transverse sections were cut at a 
thickness of 4 µm and stained with H & E (100x) 
.Images were captured with a high-resolution 
digital camera attached to a Nikon Eclipse 80i 
microscope  (Nikon Co., Tokyo, Japan) and 




All values are explicated: mean ± standard 
deviation (SD). Variation between each 
experimental groups were measured by one way 
analysis of variance (ANOVA) using the software 
SPSS 21 version (SPSS Inc., Chicago, USA) and 
least significant difference (LSD) was determined 
using post-hoc multi-comparison test. P < 0.05 




Effect of RESV on locomotive function 
 
Movement (motor function) of hind limbs were 
normal in the sham-operated control rats (Table 
1). However, the SCIR treated animals showed a 
significant reduction in hind limb movement, 
which depicts the loss of several neurons. After 
supplementation with RESV and MP, hind limb 
movement was substantially improved, thus 
lowering the incidence of neurological deficits. 
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Table 1: Effect of RESV on spinal locomotive function (BBB rating) in sham control and experimental rats 
 
Group 1st day 3rd day 5th day 7th day 
Sham (control) 20.00±0.57 20.50±0.87 21.00±0.50 21.00±1.00 
SCIR 3.24±0.13 a** 7.42±0.19 a** 10.25±0.25 a** 12.53±0.54 a** 
RESV 20+ SCIR 7.02±0.22 b* 11.50±0.59 b* 13.05±0.82 b* 15.64±0.90 b* 
RESV 40+ SCIR 8.36±0.31 b* 13.45±0.88b* 15.23±0.78 b* 18.35±0.88b** 
RESV 60+ SCIR 8.58±0.39 b* 11.24±0.79 b* 14.56±0.60 b* 16.09±0.98 b** 
MP 50+ SCIR 8.16±0.35b* 12.56±0.88 b* 14.78±1.35 b* 17.05±1.08 b** 
Values were expressed as mean ± S.D for 8 rats in each group; **p < 0.01, *p < 0.05 (a) SCIR group compared 
with the sham control group; (b) Treatment groups (RESV 20, 40, 60 and MP 50) compared with the SCIR injured 
group 
 
Effect of RESV on spinal edema 
 
As shown in Fig 1A, spinal E values were 
dramatically higher (81.35 %) in the SCIR group 
compared with the sham-operated control group. 
RESV (20, 40 and 60 mg/kg) groups showed 
lower spinal E values (65.12, 52.56 and 58.34 %, 
respectively) than SCII group; MP treatment 
resulted in an E value of 55.82 %, similar to that 
of RESV 40 group. 
 
Effect of antioxidant and lipid peroxidation 
products (MDA) 
 
The levels of antioxidant and lipid peroxidative 
products (MDA) in SCIR-injured rats were 
examined to determine whether RESV 
administration protected spinal tissue against 
oxidative stress (Table 2). The spinal SOD, CAT, 
and GSH activities were is substantially lower (p 
< 0.05) in the SCIR group than in the sham-
operated control group, whereas the MDA levels 
were markedly elevated (p < 0.05). Treatment 
with RESV significantly improved (p < 0.05) 
SOD, CAT and GSH activities as well as 
concomitantly attenuated the MDA level in spinal 
tissue. However, the MP group showed a slight 
improvement in antioxidant activity and partially 
reverted the MDA levels. RESV 40 (p < 0.01) 
showed higher antioxidant activity than other 




Figure 1: The effect of RESV on spinal edema (1A) and MPO levels (1B)in sham control and experimental 
rats.**p < 0.01, *p < 0.05; (a) SCIR group compared with the sham control group; (b) treatment groups (RESV 20, 
40, 60 and MP 50) compared with the SCIR injured group 
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Table 2: Effect of RESV on the activities of spinal antioxidants and lipid peroxidation in sham control and 
experimental rats. 
 







Control 3.79±0.45 65.80±6.15 9.03±1.41 0.67±0.08 
SCIR 2.21±0.21 a** 54.29±4.78 a** 5.83±0.72 a** 1.44±0.10 a** 
RESV 20 + SCIR 3.02±0.18 b* 58.56±5.06 b* 6.98±0.97 b* 0.94±0.07 b* 
RESV 40 +  SCIR 3.38±0.25 b* 62.99±7.62 b* 8.06±0.81 b** 0.72±0.07 b** 
RESV 60 +  SCIR 3.14±0.23 b* 60.73±5.83 b* 7.84±0.58 b* 0.89±0.03 b* 
MP 50 +  SCIR 3.08±0.22 b* 58.74±8.34 b* 7.21±0.62 b* 0.84±0.07 b* 
Data are expressed as mean ± S.D for 8 rats in each group; **p < 0.01, *p < 0.05; (a) SCIR group compared with 
the control group, (b) Treatment groups (RESV 20, 40, 60 and MP 50) compared with the SCIR injured group; ptn 
= protein. One unit (U) of SOD activity is equal to the amount of enzyme that inhibits the auto-oxidation reaction 
by 50%; one U of CAT activity was defined as 1 mg of tissue protein that consumed 1 μmol of H2O2 at 405 nm for 
1 second 
 
Effect of RESV on neutrophil infiltration 
(MPO) 
 
To evaluate the effect of RESV on neutrophil 
activation and infiltration, MPO activity was 
determined (Fig. 1B).   Compared with the SCIR 
group, the sham-operated group showed a 
decline (p < 0.05) in MPO activity. 
Supplementation with RESV and MP markedly 
attenuated the MPO activity in a dose-dependent 
fashion. 
 
Effect of RESV on activities of inflammatory 
markers 
 
The levels of these inflammatory markers in the 
spinal tissue of SCIR induced rats were higher (p 
< 0.01) as compared with sham control rats. 
Equivalence with SCIR induced rats, RESV and 
MP treatment (p < 0.01) lowered the 
concentrations of these pro-inflammatory 
cytokines, thus suggesting its anti-inflammatory 
potential. 
 
Effect of RESV on spinal section with 
hematoxylin and eosin staining 
 
Control showed normal architecture of neuron 
with a prominent nucleus (Plate 2A). The spinal 
section of SCIR treated rat portrait a higher 
degenerated neurons (hemorrhage and 
congestion) with widespread edema, increased 
cytoplasmic vacuolization and disintegrated 
nucleus (2B). However, RESV-administered rats 
(2C - E) showed fewer degenerated neurons 
(hemorrhage and congestion) compared with 
SCIR-injured animals, confirming the 
neuroprotective effects of RESV. Similarly, MP 
treatment (2F) also showed a significant 
restoration in neuronal structure, but still mild 
edema accompanied with few degenerated 
neurons. 
 













NF-p65    
(pg/mg  
protein) 
Sham control 124.56±13.30 68.65±5.78 91.23±9.41 79.47±8.34 
SCIR 290.74±19.10 a** 181.52±15.06 a** 215.38±23.02 a** 195.84±20.02 a** 
RESV 20 + SCIR 206.24±21.16 b** 122.63±11.10 b* 146.67±14.07 b* 115.75±11.03 b** 
RESV 40 + SCIR 144.28±17.33 b** 86.24±10.23  b** 105.11±10.09  b** 91.36±10.73  b** 
RESV 60 + SCIR 163.23±20.23 b** 99.45±10.00 b* 116.56±11.07 b* 102.35±9.03 b** 
MP 50 + SCIR 151.68±17.34 b** 91.24±9.23 b** 103.46±8.09  b** 99.93±09.82  b** 
Values are expressed as mean ± S.D (n = 8); **p < 0.01, *p < 0.05; (a) SCIR group compared with the sham 
control group, (b) Treatment groups (RESV 20, 40, 60 and MP 50) compared with SCIR-injured group 
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Plate 1: The effect of RESV on the spinal section stained with H & E n in sham control and experimental rats. A 
transection of control showed normal neuronal architecture  (Fig 2A, 100x magnification) (A); transaction of SCIR 
induced rats showed more r degenerated neurons (hemorrhage and congestion) with widespread edema, 
increased cytoplasmic vacuolization and disintegrated nucleus (B).  Fewer degenerated neurons (hemorrhage 
and congestion) were observed in the RESV-administered rats (C to E) than in the SCIR-injured animals, 
confirming the neuroprotective effects of RESV. Similarly, MP treatment (F) also restored neuronal structure 




Paraplegia is a fatal complication resulting from 
SCII during thoracic-abdominal aortic aneurysm 
surgery [1]. Several pathophysiological events, 
including excitotoxicity (glutamate-mediated), 
energy failure, inflammation, apoptosis, and 
oxidative stress, have been implicated in SCIR 
injury [4,5]. Among these, oxidative stress and 
inflammation are the major contributors and 
initiators of SCIR injury [4-6]. Therefore, in the 
present study, we examined the protective 
effects of RESV against SCIR injury in a dose-
dependent manner by evaluating various 
oxidative stress and inflammatory markers using 
MP as a standard. 
 
Assessment of locomotor behavior (hind limb 
movement) is an important measure of long-term 
functional recovery after SCIR injury and is a 
pivotal tool for determining the neuroprotective 
efficacy of various drugs. Our results clearly 
show the neuroprotective efficacy of both RESV 
and MP based on markedly increased BBB 
scores. This result reflects improved hind limb 
movement by preventing neuronal loss and 
mitigating the incidence of neurological deficits. 
Liu et al also suggested that RESV can 
significantly lower neurological deficits in a SCIR-
injured rabbit model [15]. 
 
Morphological abnormalities of spinal tissue are 
indirectly assessed by evaluating E based on dry 
and wet weights. During SCIR induction, a 
substantial reduction in blood flow was observed 
(due to aortic occlusion), followed by reperfusion 
(increased blood flow), which alters the 
electrolytic balance (pumps) and various 
metabolic processes in spinal tissue, leading to 
elevated water movement and eventually 
resulting in E [13,15]. Due to the vasoprotective 
effects of RESV [16], the electrolytic balance was 
significantly maintained, thus attenuating E. Our 
results are in agreement with those of Yang et al, 
who showed that RESV treatment can revert E 
successfully in the SCIR-injured rat model [17]. 
Similarly, Ren et al also inferred that RESV can 
effectively reduce E under ischemic conditions 
[18]. 
 
Considerable evidence indicates that 
overproduction of free radicals (oxidative stress) 
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and the subsequent inflammatory response 
under ischemic conditions are major factors 
contributing to various pathophysiological 
changes during SCIR injury [13,19]. Neural 
tissues are highly susceptible to free-radical 
damage due to an increased metabolic rate and 
lipid content. During SCIR, many free radicals 
are generated; to counter the excess free 
radicals the endogenous antioxidant defense 
system, which includes SOD, CAT and reduced 
GSH, is upregulated by various factors to trigger 
the Nrf2-dependent pathway. However, high 
levels of free radicals suppress normal 
antioxidant levels and ultimately contribute to 
oxidative stress. Therefore, SOD, CAT and GSH 
levels were significantly lower in SCIR-injured 
rats.  
 
Moreover, levels of the lipid peroxidation product 
MDA were elevated in the SCIR group, 
contributing to oxidative stress. RESV-
supplemented animals exhibited improved SOD 
and CAT activities and higher GSH levels, as 
well as substantially reduced MDA levels, in 
spinal tissue. Overall, RESV 40 showed better 
antioxidant activity compared with other RESV 
dosages or the MP group. Due to the free 
hydroxyl group, RESV may act as an antioxidant 
and trigger endogenous antioxidant levels to 
revert oxidative stress conditions by maintaining 
a balance between antioxidants and free radicals 
and activating the Nrf2/HO-1 pathway [20]. 
Furthermore, RESV has been reported to be a 
xanthine oxidase inhibitor and halt the synthesis 
of hypoxanthine and free radicals (ROS) under 
ischemic conditions [21]. 
 
Inflammation is the crucial event that is 
responsible for the neurological damage (SCI) 
due to ischemic reperfusion and thus has been 
proven to be a promising target for a therapeutic 
approach after SCIR injury [21]. Neutrophil and 
neuroglial activation, mobilization and infiltration 
are well-documented key factors during SCIR 
that initiate the inflammatory cascade by 
triggering NF-κB and subsequently increasing 
various pro-inflammatory cytokines such as 
tumor necrosis factor-α, IL-1β and IL-6 [22]. 
Hence, the inflammatory status of spinal tissue 
was indirectly evaluated by measuring MPO 
activity. Several reports have indicated a strong 
correlation between MPO levels and the severity 
of ischemic reperfusion injury [23]. Lafci et al also 
showed that MPO activity was significantly 
increased after SCIR injury in a rat model [24]. 
Similarly, in the present study, MPO activity in 
spinal cord tissue was significantly increased in 
response to ischemic reperfusion. The increased 
MPO activity was markedly attenuated by the 
RESV and MP treatments, indicating the 
antioxidant and anti-inflammatory activities of 
RESV. Renaud and Martinoli argued that 
treatment with RESV substantially reduces 
microglial activation and significantly inhibits the 
infiltration of neutrophils, thus diminishing MPO 
levels under ischemic conditions [25]. 
 
Overexpression of NF-κB has been positively 
correlated with a higher degree of ischemia-
induced neuronal injury [15]. Levels of pro-
inflammatory cytokines such as TNF-α, IL-1β, IL-
6, and nuclear factor NF-p65 were dramatically 
increased in the SCIR rats due to excessive 
production of free radicals which, in turn, 
triggered the neuroinflammatory cascade by 
activating various cytokines. Compared with the 
SCIR-injured rats, the RESV and MP treatments 
substantially suppressed the concentrations of 
these pro-inflammatory cytokines, indicating their 
anti-inflammatory potential. Our results are 
supported by those of Smith et al., who 
evaluated inflammatory chemokine 
concentrations (interleukin-1β, IL-6 and TNF-α) 
and reported elevated levels of these 
inflammatory cytokines after SCIR [26]. 
Furthermore, RESV can effectively improve 
cerebral blood flow by crossing the blood-brain 
barrier and exhibits protective effects against 
ischemic injury by decreasing glial cell activation 
and thus positively alleviating oxidative stress 
and the inflammatory cascade. 
 
RESV can also influence SIRT1 expression 
indirectly at the transcriptional level, block the 
translocation of NF-κB (p65) from the cytosol to 
the nucleus, and inhibit the production of various 
pro-inflammatory cytokines, especially IL-1β, IL-6 
and TNF-α. Moreover, RESV augments 
endogenous antioxidant activities, thus inhibiting 
activation of the inflammatory cascade [15]. 
 
Sham-operated control rats showed normal 
neuronal architecture with prominent nuclei. 
However, SCIR-injured rats had higher numbers 
of degenerated neurons (hemorrhage and 
congestion) with widespread E, increased 
cytoplasmic vacuolization and disintegrated 
nuclei due to increased oxidative stress and cell 
damage by lipid peroxidation (MDA). As 
explained previously, RESV and MP 
concomitantly improved the antioxidant status 
and attenuated MDA levels substantially, 
indicated by the fact that RESV- and MP-
administered rats displayed significantly fewer 
degenerated neurons (hemorrhage and 
congestion) than SCIR-injured animals, 
validating the neuroprotective effects of RESV.   
 
Liu et al [15] also demonstrated that RESV 
treatment normalized the neuronal count and 
Su et al 
Trop J Pharm Res, June 2016; 15(6): 1232  
 
function due to antioxidant, anti-inflammatory and 
anti-apoptotic activities. RESV (40 mg) exhibited 
the highest neuroprotection compared with MP 
due to its free radical-quenching activity. Our 
results are in agreement with the findings of Ates 
et al and Yang et al [12,17]. The major limitation 
of the current study is that bioenergetics 
parameters and apoptosis were not evaluated to 
confirm secondary energy failure and its 
association with RESV treatment. Additionally, 
the reason for the improved activity of RESV (40 





Both RESV and MP exhibit neurotherapeutic 
properties, reflected in various aspects, including 
substantially reduced E, oxidative stress and 
inflammation. Furthermore, RESV and MP 
exhibit spinal protective properties by 
concomitantly reverting histopathological 
abnormalities and improving the number of 
neurons. Thus, it is proposed here that RESV (40 
mg) can be used as a neurotherapeutic agent to 
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